Ocular Therapeutix Reports First Quarter 2025 Revenue Results

Published on May 6, 2025
BEDFORD, Mass.—Ocular Therapeutix, Inc. (NASDAQ: OCUL), a fully integrated biopharmaceutical company, has reported financial results for the first quarter ended March 31, 2025. Total net revenue was $10.7 million for the first quarter of 2025, a 27.6 percent decrease as compared with total net revenue of $14.8 million in the comparable quarter in 2024. The company advised that this decrease was driven by decreased gross revenues from sales of Dextenza, an FDA-approved treatment for ocular inflammation and pain after eye surgery, as well as ocular itching associated with allergic conjunctivitis. The company’s net product revenue was $10.6 million for the three months ended March 31, 2025, reflecting a decrease of $4.1 million or 27.7 percent over the comparable quarter in 2024, the announcement stated, noting that the company anticipates that net product revenue on a quarterly basis should increase for the remainder of 2025. In making the announcement, the company also shared key business highlights.
Continue reading on website
Other news

ARVO 2025: Exploring a conversion factor between 2 OCT devices to monitor glaucoma progression

May 5, 2025
Hammond and his team focused on creating a reliable conversion factor between 2 widely used optical coherence tomography (OCT) systems—the TopCon Maestro2 and the ZEISS Cirrus 5000. Their work specifically looked at ganglion cell–inner plexiform layer and retinal nerve fiber layer thickness measurements, which are critical markers in glaucoma diagnosis and monitoring.

North Dakota optometric advocates establish telemedicine guidelines in HB 1267

May 6, 2025
The bill is the product of a 2-year collaborative effort by the North Dakota Optometric Association (NDOA) and the North Dakota State Board of Optometry.